Publication:
Partial IGF-1 deficiency is sufficient to reduce heart contractibility, angiotensin II sensibility, and alter gene expression of structural and functional cardiac proteins.

dc.contributor.authorGonzález-Guerra, José Luis
dc.contributor.authorCastilla-Cortazar, Inma
dc.contributor.authorAguirre, Gabriel A
dc.contributor.authorMuñoz, Úrsula
dc.contributor.authorMartín-Estal, Irene
dc.contributor.authorÁvila-Gallego, Elena
dc.contributor.authorGranado, Miriam
dc.contributor.authorPuche, Juan E
dc.contributor.authorGarcía-Villalón, Ángel Luis
dc.date.accessioned2023-01-25T09:50:33Z
dc.date.available2023-01-25T09:50:33Z
dc.date.issued2017-08-14
dc.description.abstractCirculating levels of IGF-1 may decrease under several circumstances like ageing, metabolic syndrome, and advanced cirrhosis. This reduction is associated with insulin resistance, dyslipidemia, progression to type 2 diabetes, and increased risk for cardiovascular diseases. However, underlying mechanisms between IGF-1 deficiency and cardiovascular disease remain elusive. The specific aim of the present work was to study whether the partial IGF-1 deficiency influences heart and/or coronary circulation, comparing vasoactive factors before and after of ischemia-reperfusion (I/R). In addition, histology of the heart was performed together with cardiac gene expression for proteins involved in structure and function (extracellular matrix, contractile proteins, active peptides); carried out using microarrays, followed by RT-qPCR confirmation of the three experimental groups. IGF-1 partial deficiency is associated to a reduction in contractility and angiotensin II sensitivity, interstitial fibrosis as well as altered expression pattern of genes involved in extracellular matrix proteins, calcium dynamics, and cardiac structure and function. Although this work is descriptive, it provides a clear insight of the impact that partial IGF-1 deficiency on the heart and establishes this experimental model as suitable for studying cardiac disease mechanisms and exploring therapeutic options for patients under IGF-1 deficiency conditions.
dc.identifier.doi10.1371/journal.pone.0181760
dc.identifier.essn1932-6203
dc.identifier.pmcPMC5555709
dc.identifier.pmid28806738
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555709/pdf
dc.identifier.unpaywallURLhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0181760&type=printable
dc.identifier.urihttp://hdl.handle.net/10668/11498
dc.issue.number8
dc.journal.titlePloS one
dc.journal.titleabbreviationPLoS One
dc.language.isoen
dc.organizationHospital Universitario Puerta del Mar
dc.page.numbere0181760
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.meshAngiotensin II
dc.subject.meshAnimals
dc.subject.meshBody Weight
dc.subject.meshBradykinin
dc.subject.meshExtracellular Matrix
dc.subject.meshGene Expression Regulation
dc.subject.meshHemodynamics
dc.subject.meshInsulin-Like Growth Factor I
dc.subject.meshMice, Transgenic
dc.subject.meshMyocardial Contraction
dc.subject.meshMyocardium
dc.subject.meshOrgan Size
dc.subject.meshPerfusion
dc.subject.meshReal-Time Polymerase Chain Reaction
dc.subject.meshVasoconstriction
dc.subject.meshVasodilation
dc.titlePartial IGF-1 deficiency is sufficient to reduce heart contractibility, angiotensin II sensibility, and alter gene expression of structural and functional cardiac proteins.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number12
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC5555709.pdf
Size:
11.05 MB
Format:
Adobe Portable Document Format